Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

381. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy

Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging (...) in patients receiving long-term oral anticoagulant therapy Spyropoulos A C, Frost F J, Hurley J S, Roberts M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low molecular weight heparin (LMWH) during the perioperative period

NHS Economic Evaluation Database.2004

382. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack.

Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. BACKGROUND: People with nonrheumatic atrial fibrillation (NRAF) who have had a transient ischaemic attack (TIA) or a minor ischaemic stroke are at high risk of recurrent stroke. OBJECTIVES: The objective of this review was to assess the effect of anticoagulants for secondary prevention, after a stroke or TIA, in patients with NRAF. SEARCH STRATEGY: We (...) searched the Cochrane Stroke Group trials register (9 June 2003) and contacted trialists. SELECTION CRITERIA: Randomised trials comparing oral anticoagulants with control (no therapy) or placebo in people with NRAF and a previous TIA or minor ischaemic stroke. Control groups on aspirin did not meet the selection criteria. DATA COLLECTION AND ANALYSIS: Both reviewers assessed trial quality and extracted data. MAIN RESULTS: Two trials involving 485 people were included. Follow-up time was 1.7 years

Cochrane2004

383. Anticoagulants for acute ischaemic stroke.

Anticoagulants for acute ischaemic stroke. BACKGROUND: Most ischaemic strokes are caused by blood clots blocking an artery in the brain. Clot prevention with anticoagulant therapy could have a significant impact on patient survival, disability and stroke recurrence. OBJECTIVES: The objective of this review was to assess the effect of anticoagulant therapy versus control in the early treatment of patients with acute ischaemic stroke. SEARCH STRATEGY: We searched the Cochrane Stroke Group trials (...) register (last searched 30 October 2003). For previous updates of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. SELECTION CRITERIA: Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in patients with acute presumed or confirmed ischaemic stroke. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected trials

Cochrane2004

384. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. BACKGROUND: The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR. METHODS: We studied (...) percent confidence interval, 1.1 to 10.1). An INR of 1.5 to 1.9 at admission was associated with a mortality rate similar to that for an INR of less than 1.5 (18 percent and 15 percent, respectively). The 30-day mortality rate among patients who were taking aspirin at the time of the stroke was similar to that among patients who were taking warfarin and who had an INR of less than 2.0. CONCLUSIONS: Among patients with nonvalvular atrial fibrillation, anticoagulation that results in an INR of 2.0

NEJM2003

385. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Clinical impact of bleeding in pa... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 139 , Issue: 11 , Publisher: Am Coll Physicians , Pages: 893-900 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Clinicians should consider the clinical (...) impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism. PURPOSE: To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding. DATA SOURCES: MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only. STUDY

Annals of Internal Medicine2003

386. Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment

Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment de Sola-Morales O Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation de Sola-Morales O. Portable coagulometers: revision of the scientific evidence and economic assessment of their use in self-control of oral anticoagulant treatment. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN06/2003. 2003 Authors' objectives The endpoints of this study were to evaluate

Health Technology Assessment (HTA) Database.2003

387. Perioperative management of patients receiving oral anticoagulants: a systematic review

Perioperative management of patients receiving oral anticoagulants: a systematic review Perioperative management of patients receiving oral anticoagulants: a systematic review Perioperative management of patients receiving oral anticoagulants: a systematic review Dunn A S, Turpie A G CRD summary This review assessed the peri-operative management and outcomes of patients receiving long-term oral anticoagulant therapy. The authors concluded that for invasive and surgical procedures, oral (...) anticoagulation needs to be withheld and further treatment decisions individualised. The review methodology was poorly reported and the authors' conclusions may be subject to a number of biases. Authors' objectives To assess the peri-operative management and outcomes of patients receiving long-term oral anticoagulant (OAC) therapy. Searching MEDLINE was searched from January 1966 to June 2001 for publications in the English language; the search terms were reported. The Cochrane Library was also searched

DARE.2003

388. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants

Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants (...) Iorio A, Guercini F, Pini M CRD summary This review compared long term low molecular weight heparin (LMWH) treatment of venous thromboembolism with oral anticoagulation. The authors concluded that LMWH for 3 months is as safe and effective as oral anticoagulation in preventing the recurrence of venous thromboembolism. The authors' conclusions are likely to be reliable. Authors' objectives To compare the efficacy and safety of long term treatment of venous thromboembolism (VTE) using

DARE.2003

389. Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis

Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Cost-saving approach to patients on long-term anticoagulation who need endoscopy: a decision analysis Mathew A, Riley T R, Young M, Ouyang A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three management strategies for anticoagulation in patients undergoing an urgent or elective endoscopy were considered. The first was an initial diagnostic endoscopy without altering anticoagulation therapy, followed by therapeutic endoscopy if required. The second option was termed the "heparin window approach". This involved

NHS Economic Evaluation Database.2003

390. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. BACKGROUND: Bleeding associated with warfarin anticoagulation correlates directly to duration and degree of international normalized ratio (INR) elevation above the therapeutic range. Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications. OBJECTIVE: To evaluate the efficacy and safety of human recombinant factor VIIa (rFVIIa (...) ) concentrate in persons requiring rapid reversal of the effects of warfarin. DESIGN: Uncontrolled case series. SETTING: Academic medical center. PATIENTS: 13 patients with critically increased INRs requiring immediate reversal of warfarin-induced anticoagulation. MEASUREMENTS: Prothrombin time and INR were measured before and after administration of varying doses of rFVIIa. RESULTS: Critically prolonged INR and bleeding complications were treated successively and rapidly in all patients, regardless

Annals of Internal Medicine2002

391. Oral anticoagulation and risk of death: a medical record linkage study.

Oral anticoagulation and risk of death: a medical record linkage study. OBJECTIVE: To study how mortality varies with different degrees of anticoagulation reflected by the international normalised ratio (INR). DESIGN: Record linkage analysis with death hazard estimated as a continuous function of INR. DATA SOURCES: 46 anticoagulation clinics in Sweden with computerised medical records. SUBJECTS: Records for 42 451 patients, 3533 deaths, and 1.25 million INR measurements. MAIN OUTCOME MEASURES (...) , 1069 deaths occurred within 7 weeks; if the risk coincided with that with an INR of 2.9, the expected number of deaths would have been 569. Thus at least 500 deaths were associated with a high INR value, but not necessarily caused by the treatment. CONCLUSIONS: The excess mortality associated with high INR values supports the use of less intensive treatment and a small therapeutic window, with INR close to 2.2-2.3 irrespective of the indication for anticoagulant treatment. More preventive actions

BMJ2002 Full Text: Link to full Text with Trip Pro

392. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. CONTEXT: Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of underanticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant forms with reduced activity have been identified, CYP2C9*2 and CYP2C9*3. Patients (...) with these genetic variants have been shown to require lower maintenance doses of warfarin, but a direct association between CYP2C9 genotype and anticoagulation status or bleeding risk has not been established. OBJECTIVE: To determine if CYP2C9*2 and CYP2C9*3 variants are associated with overanticoagulation and bleeding events during warfarin therapy. DESIGN AND SETTING: Retrospective cohort study conducted at 2 anticoagulation clinics based in Seattle, Wash. PARTICIPANTS: Two hundred patients receiving long

JAMA2002

393. Anticoagulation therapy as prophylaxis for prevention of DVT or pulmonary embolism in neurosurgery

Anticoagulation therapy as prophylaxis for prevention of DVT or pulmonary embolism in neurosurgery Anticoagulation therapy as prophylaxis for prevention of DVT or pulmonary embolism in neurosurgery Anticoagulation therapy as prophylaxis for prevention of DVT or pulmonary embolism in neurosurgery Abdulwadud O Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Abdulwadud O. Anticoagulation therapy as prophylaxis for prevention of DVT or pulmonary embolism in neurosurgery. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2002: 12 Authors' objectives This aim of this critical appraisal was to assess the effectiveness of anticoagulation therapy as prophylaxis for prevention of deep vein thrombosis (DVT) or pulmonary embolism in neurosurgery. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Anticoagulants; Neurosurgery; Pulmonary

Health Technology Assessment (HTA) Database.2002

394. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis

Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis Desbiens N A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was anticoagulation treatment with warfarin in patients with nonrheumatic atrial fibrillation (AF). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients aged 65 to 100 years with nonrheumatic AF. Setting

NHS Economic Evaluation Database.2002

395. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management

A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management Fitzmaurice D A, Murray E T, Gee K M, Allan T F, Hobbs F D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Patient self-management of oral anticoagulation treatment (i.e. warfarin) was studied. The self-management approach involved two training sessions of between one and two hours where patients were taught how to test

NHS Economic Evaluation Database.2002

396. Testing strategies for diagnosing lupus anticoagulant: decision analysis

Testing strategies for diagnosing lupus anticoagulant: decision analysis Testing strategies for diagnosing lupus anticoagulant: decision analysis Testing strategies for diagnosing lupus anticoagulant: decision analysis Segal J B, Lehmann H P, Petri M, Mueller L, Kickler T S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Various testing strategies for the detection of lupus anticoagulant (LA) were considered. The testing strategies were different combinations of three tests: a prolonged activated partial thromboplastin time (aPTT) assay prolonged with negative mixing studies and a platelet neutralisation procedures (PNP) assay that suggested the presence of LA; dilute Russell viper venom times (dRVVT) assays; and tissue

NHS Economic Evaluation Database.2002

397. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. OBJECTIVE: To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation. DESIGN: Prospective observational study. SETTING: Tertiary and peripheral referral centres in Nova Scotia, Canada

BMJ2001 Full Text: Link to full Text with Trip Pro

398. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin.

Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. BACKGROUND: An elevated international normalized ratio (INR) increases the risk for major hemorrhage during warfarin therapy. Optimal management of patients with asymptomatic elevations in INR is hampered by the lack of understanding of the time course of INR decay after cessation of warfarin therapy. OBJECTIVE: To identify (...) predictors of the rate of INR normalization after excessive anticoagulation. DESIGN: Retrospective cohort study. SETTING: Outpatient anticoagulant therapy unit. PATIENTS: Outpatients with an INR greater than 6.0 were identified from August 1993 to September 1998. Patients in whom two doses of warfarin were withheld and a follow-up INR was obtained on the second calendar day were enrolled. No patient received vitamin K(1). MEASUREMENTS: The INR was measured 2 days after an INR greater than 6.0

Annals of Internal Medicine2001

399. In patients with cerebral metastases is anticoagulation therapy for thromboembolic disease associated with an increased risk of cerebral haemorrhage?

In patients with cerebral metastases is anticoagulation therapy for thromboembolic disease associated with an increased risk of cerebral haemorrhage? In patients with cerebral metastases is anticoagulation therapy for thromboembolic disease associated with an increased risk of cerebral haemorrhage? In patients with cerebral metastases is anticoagulation therapy for thromboembolic disease associated with an increased risk of cerebral haemorrhage? Burrows E Record Status This is a bibliographic (...) record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Burrows E. In patients with cerebral metastases is anticoagulation therapy for thromboembolic disease associated with an increased risk of cerebral haemorrhage? Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2001: 11 Authors' objectives This aim of this report was to assess the risk of cerebral haemorrhage in patients with cerebral metastases

Health Technology Assessment (HTA) Database.2001

400. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation

Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation Taylor F C, Cohen H, Ebrahim S Authors' objectives To examine the benefits and risks of long-term anticoagulation (warfarin (...) ) compared with antiplatelet treatment (aspirin, indobufen) in patients with non-rheumatic atrial fibrillation. Searching The CENTRAL Register on the Cochrane Library, EMBASE, MEDLINE, CINAHL and SIGLE were searched from 1966 to 1999 using the terms 'atherosclerosis', 'atrial fibrillation', 'myocardial infarction' or 'coronary disease' and 'anticoagulation' and a RCT filter (see Other Publications of Related Interest no.1). In addition, the authors checked references in relevant papers and approached key

DARE.2001